Early data shows ButanVac vaccine induces potent immune response

Developed by the Sao Paulo-based Butantan Biological Institute, the ButanVac coronavirus vaccine showed ' an acceptable safety profile and potent immunogenicity' in clinical trials held in Thailand. The study showed that there were 'no vaccine-related serious adverse events.' The vaccine is also being tested in Brazil and Vietnam, but trial data from the two countries have not been made available so far.